Related Experiment Video
Updated: Apr 30, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.0K
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
O Middleton1, E Cosimo1, E Dobbin2
1Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Leukemia
|May 3, 2014
Summary
Complement defects in chronic lymphocytic leukemia (CLL) patients reduce complement-dependent cytotoxicity (CDC) during anti-CD20 monoclonal antibody (MAb) therapy. Supplementing with fresh-frozen plasma may improve treatment efficacy in these patients.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Monoclonal antibodies (MAbs), such as rituximab (RTX) and ofatumumab (OFA), are crucial in treating chronic lymphocytic leukemia (CLL).
- The efficacy of anti-CD20 MAbs relies on complement-dependent cytotoxicity (CDC).
- Complement deficiencies in CLL patients may impair MAb-induced CDC responses.
Purpose of the Study:
- To investigate the impact of complement defects on CDC induction by anti-CD20 MAbs in CLL patients.
- To compare the CDC-inducing capabilities of ofatumumab and rituximab in CLL.
- To explore strategies for restoring CDC in CLL patients with complement deficiencies.
Main Methods:
- Patient serum samples were analyzed for complement component levels and CDC activity.
- CDC was measured using anti-CD20 MAbs (rituximab and ofatumumab) against CLL cells.
- Complement activity was assessed after secondary challenge with MAbs, with and without serum supplementation.
Main Results:
- Ofatumumab induced higher CDC than rituximab, particularly in poor-prognosis CLL subgroups.
- 38.1% of CLL patients exhibited deficiencies in one or more complement components, correlating with reduced CDC.
- Complement components were exhausted in CLL patients post-treatment, and supplementation with normal human serum or C2 restored CDC.
- High CLL cell counts led to rapid complement exhaustion.
Conclusions:
- Complement deficiencies and exhaustion significantly impair anti-CD20 MAb efficacy in CLL patients.
- Ofatumumab demonstrates superior CDC induction compared to rituximab in CLL.
- Supplementation with fresh-frozen plasma or specific complement components may enhance CDC and improve therapeutic outcomes in CLL patients with complement defects or high tumor burden.
